UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1214, 2025

SYRA HEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware	001-41822	85-4027995
(State or other jurisdiction	(Commission	(I. R. S. Employer
of incorporation)	File Number)	Identification No.)

1119 Keystone Way N. #201

Carmel, IN 46032

(Address of principal executive offices, including zip code)

(463) 345-8950

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.001 par value		SYRA		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.~~02.~~07 ~~Results~~Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Conditions.~~Vote of Security Holders

On November 1214, 2025, Syra Health Corp. ~~issued~~(the a“Company”) ~~press~~held ~~release announcing~~ its ~~financial~~Annual ~~results~~Meeting ~~for~~of Stockholders (the ~~third~~“Annual ~~quarter~~Meeting”). A ~~ended~~total ~~September~~of 3015,848,410 shares of common stock (including 600,000 shares of Class B common stock with each share of Class B common stock ~~2025~~having 16.5 Avotes ~~copy~~per share), constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the ~~press~~matters ~~release~~submitted isto ~~furnished~~a vote of stockholders at the Annual Meeting, as ~~Exhibit~~set ~~99.1~~forth toin ~~this~~the ~~Form~~Definitive ~~8-K.~~Proxy Statement, filed with the Securities and Exchange Commission on September 19, 2025 are as follows:

~~The~~Proposal ~~information in this report, including Exhibit 99.~~1,. ~~shall~~All ~~not~~of bethe ~~deemed~~five to(5) benominees ~~“filed”~~ for ~~purposes~~director ofwere ~~Section~~elected 18to ofserve until the ~~Securities and~~2026 ~~Exchange~~Annual ~~Act~~Meeting of ~~1934,~~Stockholders ~~as amended (the “Exchange Act”),~~ or ~~otherwise~~until ~~subject~~their torespective successors ~~the~~have ~~liabilities~~been ofduly ~~that~~elected ~~Section,~~ and ~~shall not be incorporated by reference into any filing under the Securities Act of 1933~~qualified, ~~as amended,~~ or ~~the~~until ~~Exchange Act, except as shall be expressly set forth by specific reference in~~ such adirector’s ~~filing.~~earlier ~~In addition~~resignation, ~~the~~removal ~~exhibit~~or ~~furnished~~death. ~~herewith~~The ~~contain~~result ~~statements intended as~~of ~~“forward-looking~~the ~~statements”~~votes ~~that are subject~~ to elect the ~~cautionary~~five ~~statements~~(5) ~~about~~directors ~~forward-looking~~was ~~statements~~as ~~set forth in such exhibit.~~follows:

Item 9.01 Financial Statements and Exhibit

Directors	For	Against	Abstain	Broker Non Vote
Priya Prasad	9,093,067	-	4,508,108	2,247,235
Dr. Vijayapal R. Reddy	9,091,897	-	4,509,278	2,247,235
Dr. Ketan Paranjape	9,093,067	-	4,508,108	2,247,235
Dr. Avutu S. Reddy	9,091,917	-	4,509,258	2,247,235
Radhika Mereddy	8,897,555	-	4,703,620	2,247,235

~~(d)~~Proposal ~~Exhibits~~2. The appointment of M&K CPAs, PLLC, as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2025 was ratified and approved by the stockholders by the votes set forth in the table below:

The following exhibits are filed with this Current Report on Form 8-K:

For			Against			Abstain			Broker Non Vote
14,955,596			369,733			523,081			-

Exhibit Number		Description
99.1		Press Release dated November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Proposal 3. The amendment to the Company’s Amended and Restated Certificate of Incorporation to delete Article IV, Section 4.2.8(D) in its entirety which allows for the automatic conversion of Class B Common Stock upon death of a Class B stockholder was approved by the stockholders by the votes set forth in the table below:

For			Against			Abstain			Broker Non Vote
8,917,010			4,632,013			52,152			2,247,235

Proposal 4. The amendment to Section 4.2.8 of the Company’s Amended and Restated Certificate of Incorporation to add immediate family members, heirs, successors and assigns as parties to whom the Class B stockholder can transfer shares to without such Class B shares being converted was approved by the stockholders by the votes set forth in the table below:

For			Against			Abstain			Broker Non Vote
8,880,105			4,631,020			90,050			2,247,235

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYRA HEALTH CORP.
Date: November 12, 2025	By:	/s/ Priya Prasad
Date: November 14, 2025	By:	/s/ Priya Prasad
		Priya Prasad Interim Chief Executive Officer and Chief Financial Officer
		Priya Prasad
		Interim Chief Executive Officer and Chief Financial Officer

-3-

Filing Compare · Syra Health Corp